Early-Stage TNBC: What are the Roles of PARPIs?
Offered By: The University of Chicago via Independent
Course Description
Overview
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series.
Educational Partner: The Academy for Continued Healthcare Learning (ACHL)
Medium: Online Presentation
Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc.
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Syllabus
At the conclusion of this activity, participants will be able to:
- Discuss new targeted treatment approaches in the setting of triple-negative breast cancer;
- Assess the current evidence and treatment recommendations with the PARPIs for TNBC;
- Implement strategies to facilitate the use of novel therapies for TNBC in community-based settings.
Tags
Related Courses
An Evidence-Based Approach to the Diagnosis and Management of Migraines in Adults in the Primary Care and General Neurology SettingStanford University via edX To Prescribe or Not To Prescribe? Antibiotics and Outpatient Infections
Stanford University via edX Free of Pain #1 - release back originated pains by yourself
Udemy The Clinical Picture of Celiac Disease and How to Make the Diagnosis
Columbia University via Independent How Common is Celiac Disease Around the World? Role of Gluten Timing and Quantity, and Environmental Risk Factors
Columbia University via Independent